Inclusion Criteria:

- Unresectable hepatic metastases of a carcinomatous origin with exception of HCC,
biliary or bile duct carcinoma

- At least one measurable hepatic metastases > 20 mm in diameter (measured in MRI)

- Last application of palliative chemotherapy (drug dependent on the primary tumor) at
least 7 days ago

- Gender: male and female (at least 6 individuals of each gender)

- Age >= 18 years

- Negative pregnancy test (females of childbearing potential)

- Willingness to perform double-barrier-contraception during the study and for 6 month
post study medication

- ECOG performance status 0,1 or 2

- Assumed life expectancy of > 3 month

- Signed informed consent

Exclusion Criteria:

- History of significant liver pathology (other than metastases, e.g. cirrhosis of the
liver, PSC, PBC) or liver transplantation

- Laboratory tests (hematology, chemistry) outside specific limits:

- ANC <= 1.0 x 10^9/L

- Platelets <= 100 x 10^9/L

- Hb <= 9.0 g/dL (<= 5.6 mmol/L)

- Total Bilirubin > 2.0 mg/dL

- Serum Creatinine > 1.5 mg/dL

- Renal insufficiency with a GFR < 60 mL/min

- Currently ongoing taxane-containing palliative chemotherapy regimen or history of
taxane administration within 4 weeks prior to study entry

- Pregnancy or nursing status

- Positive HIV, HBV or HCV testing

- The patient has a contraindication for MRI or CEUS according to accepted clinical
guidelines

- Known hypersensitivity to any component of the EndoTAG®-1 formulation,
gadolinium-based MR-contrast media or sulphur hexafluoride

- Claustrophobia or history of active or significant neurological disorder and/or
psychiatric disorder that would prohibit the understanding and giving of informed
consent, or would interfere in the clinical and radiological evaluation of the
patient during the trial

- Concurrent treatment with other experimental drugs. Participation in another clinical
trial with any investigational drug within 30 days prior to study entry